What are the top competitors of Biogen Inc. in Healthcare sector?

The top competitors of Biogen Inc. in the Healthcare sector are: Bristol-Myers Squibb Company (BMY.SW), DocMorris AG (ROSE.SW), DocMorris AG (DOCM.SW), Johnson & Johnson (JNJ.SW).

Which has better valuations & earnings, Biogen Inc. or its competitors?

Biogen Inc. has a market cap of 21.6B and a Dividend Yield of N/A compared to its competitors.

Which stock is more profitable: Biogen Inc. or its competitors?

Biogen Inc. has an EPS of CHF6.80, while BMY.SW has an EPS of CHF2.69. So, Biogen Inc. is more profitable compared to BMY.SW.

What is Biogen Inc. stock volatility and risk in terms of investment?

Biogen Inc. has daily volatility of 0% as compared to its competitor BMY.SW which is 0%. Biogen Inc. is less volatile as compared to competitors and has low risk.

Is Biogen Inc. stock profitable?

Biogen Inc. has a Return on Equity (ROE) of 0.07%. So, Biogen Inc. is more profitable.

What is Biogen Inc. stock’s 52 weeks high and low?

Biogen Inc. stock has a 52-week high of (CHF232) and a low of (CHF131.09).

What was the average volume of Biogen Inc. stock?

The average volume of Biogen Inc. is (0) in terms of investment.

Biogen Inc. (BIIB.SW) Competitors

Biogen Inc. (BIIB.SW) Stock Competitors & Peer Comparison

See (BIIB.SW) competitors and their performances in Stock Market.

Peer Comparison Table: Medical - Pharmaceuticals Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

Symbol	Price	Change %	Market Cap	P/E Ratio	EPS	Dividend Yield
BIIB.SW	CHF 147.46	-36.44%	21.6B	21.69	CHF 6.80	N/A
BMY.SW	CHF 42.54	-4.40%	70.7B	15.81	CHF 2.69	+3.50%
ROSE.SW	CHF 35.02	N/A	404.5M	-2.28	-CHF 15.35	N/A
DOCM.SW	CHF 4.74	-1.25%	230.5M	-1.04	-CHF 4.58	N/A
JNJ.SW	CHF 193.57	+4.86%	0	N/A	N/A	+0.52%

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

BIIB.SW vs BMY.SW Comparison March 2026

BIIB.SW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIIB.SW stands at 21.6B. In comparison, BMY.SW has a market cap of 70.7B. Regarding current trading prices, BIIB.SW is priced at CHF 147.46, while BMY.SW trades at CHF 42.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIIB.SW currently has a P/E ratio of 21.69, whereas BMY.SW's P/E ratio is 15.81. In terms of profitability, BIIB.SW's ROE is +0.07%, compared to BMY.SW's ROE of +0.37%. Regarding short-term risk, BIIB.SW and BMY.SW have similar daily volatility (0.00).Check BMY.SW's competition here

Biogen Inc.